Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

It is also the second TROP2-targeting ADC to reach the EU market after Gilead Sciences' Trodelvy (sacituzumab govitecan), which was approved for a similar HR-positive, HER2-negative breast cancer ...